Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.
about
Considerations for observational research using large data sets in radiation oncologyRefining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterionOutcomes of localized prostate cancer following conservative managementChallenges in translating endpoints from trials to observational cohort studies in oncologyPatterns of colorectal cancer care in the United States and Canada: a systematic reviewSEER cancer registry biospecimen research: yesterday and tomorrowCost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adultsCombining COPD with clinical, pathological and demographic information refines prognosis and treatment response prediction of non-small cell lung cancerEndocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part DOutcomes following local therapy for early-stage breast cancer in non-trial populationsThe Effects of Hospital Characteristics on Delays in Breast Cancer Diagnosis in Appalachian Communities: A Population-Based Study.Adoption of ipilimumab in the United States: a Medicare study.Readmission predicts 90-day mortality after esophagectomy: Analysis of Surveillance, Epidemiology, and End Results Registry linked to Medicare outcomes.Diabetes management before and after cancer diagnosis: missed opportunity.Radiation therapy after radical prostatectomy for prostate cancer: evaluation of complications and influence of radiation timing on outcomes in a large, population-based cohort.Readmission after lung cancer resection is associated with a 6-fold increase in 90-day postoperative mortality.Risk prediction and clinical model building for lymph node metastasis in papillary thyroid microcarcinoma.The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer.The impact of chronic conditions on the economic burden of cancer survivorship: a systematic reviewPostoperative mortality is an inadequate quality indicator for lung cancer resection.Identifying specific chemotherapeutic agents in Medicare data: a validation studyTreatment-related complications of radiation therapy after radical prostatectomy: comparative effectiveness of intensity-modulated versus conformal radiation therapy.Data for cancer comparative effectiveness research: past, present, and future potential.Translating research into practice: the role of provider-based research networks in the diffusion of an evidence-based colon cancer treatment innovation.Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adultsComparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer.Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancerEarly stage breast cancer treatments for younger Medicare beneficiaries with different disabilities.The role of poverty rate and racial distribution in the geographic clustering of breast cancer survival among older women: a geographic and multilevel analysis.Contemporary risk profile of prostate cancer in the United States.Explaining black-white differences in receipt of recommended colon cancer treatmentAn observational study of the prevalence and incidence of comorbid conditions in older women with breast cancerAndrogen deprivation therapy and cataract incidence among elderly prostate cancer patients in the United States.Muddy water? Variation in reporting receipt of breast cancer radiation therapy by population-based tumor registriesIntensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: predictors of use and association with toxicities.Distinguishing screening from diagnostic mammograms using Medicare claims data.Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States.Use of multiple imputation to correct for bias in lung cancer incidence trends by histologic subtype.
P2860
Q24289442-75C61CDC-8C6A-4A33-A0F5-9598EEE38E01Q24633990-CF322DB3-876B-4247-9F72-9060FD7E2940Q24647380-546077EC-2134-4A12-8785-5ECBE79E2619Q26746190-5520F24F-B2E9-43C7-A1F8-BC89CD05061CQ26863029-8FFB3F78-0B72-443C-9997-F8FE34686C27Q26998744-D92137BC-E572-4636-8E00-25916CD5F926Q27309908-8ABE43BB-266B-4DA7-AF16-D3142A7C6D51Q28388778-742A85E6-F593-4078-9ED6-234577306320Q28657951-EEC25C56-631F-4A88-8DF2-B843C296305DQ28749604-6CFAADA7-1B7B-4E0B-9BFC-1F3BABBB3766Q30274959-E18E8E86-89E8-4CA8-B579-A610BEA19585Q30276953-1DE6B566-7637-4FBF-8616-F8DA0B18FE34Q30278612-A19BCED1-A395-49D2-A5A6-015023F30EBFQ30299911-A37CB585-BA92-4D2D-932A-9BA512ADC4FEQ30300626-D9E90C90-B4F6-4075-974B-2560CDC710A1Q30370176-B9EAE5A3-E19E-4DAC-90A6-450A0BCDBBD9Q30374928-6391CCA0-B935-4336-A3F3-777FF521962EQ30375537-5B414CDC-F079-4099-BD2D-DF23D527BABDQ30393166-3BE1D49F-2903-4C96-BE99-D4A65727745AQ30407624-B1CD6D04-9DBA-4F25-8D9B-7DB133CB7FC7Q30413422-7C4219D5-A4FF-4405-91EB-A3075497F870Q30413727-03C242FE-CF1F-4C29-883E-9A442399A6FDQ30416509-71EAF7F4-2C91-4888-9E96-920C18D15DEBQ30417975-CA0CCAFF-68DC-4397-BA43-4DCCDE1624C0Q30418160-1DADEFD0-0C37-425B-BFF3-73A10D305AB4Q30418988-7180DCC5-1640-4FB2-9DD2-72514E27A6C4Q30422095-C9FA77B2-E08E-4365-913E-8CA255B6A4CDQ30422372-0F907B07-97AE-4C1E-A64A-264393272063Q30422446-89AC0E8F-CA1F-4EBE-9CD3-6F45A4F9419BQ30486413-F14FA91C-F214-4D2D-886B-3B8AB0AEDF05Q30489541-349C95B8-AA45-4F62-BA73-B95A3E2A197BQ30490241-FF385EA5-E338-491A-95DB-460AEA136F72Q30502576-90650CEB-0299-4BB3-B644-7ABF2609D1E0Q30519487-EC78A78A-3485-4CB3-B89F-1AE371B786CCQ30549679-3C136B2B-BE15-4955-90E2-A75DD028C414Q30557544-97D56432-B4A5-4B78-BFC3-8B2DC2EED298Q30557710-11C2C7FD-725F-4658-AA5D-06BE8B611EF3Q30559155-E139A3DF-A25E-438E-AFDA-2DA4C7C8A47FQ30584496-EAD569B3-92A6-45DA-9135-A88161CFB97EQ30585673-0387EA3A-0337-414C-8119-9AF912A8154F
P2860
Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Overview of the SEER-Medicare ...... ted States elderly population.
@ast
Overview of the SEER-Medicare ...... ted States elderly population.
@en
type
label
Overview of the SEER-Medicare ...... ted States elderly population.
@ast
Overview of the SEER-Medicare ...... ted States elderly population.
@en
prefLabel
Overview of the SEER-Medicare ...... ted States elderly population.
@ast
Overview of the SEER-Medicare ...... ted States elderly population.
@en
P2093
P1433
P1476
Overview of the SEER-Medicare ...... ted States elderly population.
@en
P2093
Carrie N Klabunde
Deborah Schrag
Gerald F Riley
Joan L Warren
Peter B Bach
P304
P356
10.1097/01.MLR.0000020942.47004.03
P433
P577
2002-08-01T00:00:00Z